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We evaluated proarrhythmic risk of intravenous oseltamivir with chronic atrioventricular block canine
model (n ¼ 4) and action-potential assay on guinea-pig right ventricle (n ¼ 5). Oseltamivir in doses of 3
e30 mg/kg, i.v. did not induce torsade de pointes in the canine model, whereas that in concentrations of
30e300 mM decreased maximum rate of phase 0 depolarization, shortened action potential duration at
30%, 60% and 90% repolarization levels, but prolonged difference in action-potential duration between
30% and 90% repolarization levels in a concentration-related manner. These results indicate that osel-
tamivir will not induce torsade de pointes clinically, since it inhibits both inward and outward currents.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Oseltamivir (Tamiﬂu®) is a well-established medication against
inﬂuenza virus infection (1), and its intravenous formulation is
being developed for patients who cannot take oral medication
because of intubation, unconsciousness and/or vomiting (2,3).
Cardiac safety studies using the halothane-anesthetized dogs and
isolated guinea-pig atria have shown that intravenous oseltamivir
in a dose of 30 mg/kg can suppress the sinus nodal automaticity,
ventricular contraction and atrioventricular as well as intraven-
tricular conduction; and delays the ventricular repolarization in a
use-dependent manner, which are considered to be exerted
through a combination of Naþ, Ca2þ and Kþ channel inhibition in
the heart (4,5). Meanwhile, phase I studies of single intravenous
oseltamivir up to 400 mg have been conducted in healthy subjects
(2), and phase II/III studies of intravenous oseltamivir of 100 or
200 mg every 12 h for 5 days for the treatment of inﬂuenza were
performed in adults and adolescents (3), clarifying that oseltamivirgy, Faculty of Medicine, Toho
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d/4.0/).would hardly affect the electrocardiograms, laboratory ﬁndings or
vital signs (2,3). Since information obtained from healthy subjects
or patients with the intact hearts may not necessarily reﬂect the
extent of proarrhythmic risk of intravenous oseltamivir, we evalu-
ated it by using the chronic atrioventricular block canine model
(6,7) which is known to have common pathophysiological changes
in the heart to those in patients who are the most sensitive to the
drug-induced long QT syndrome (8). Furthermore, we assessed the
effects of oseltamivir on the action potential of the right ventricular
preparation of guinea pigs to conﬁrm its underlying ionic mecha-
nisms (9).
All experiments were approved by the Animal Research Com-
mittee for Animal Experimentation of Toho University (No.13-53-
152) and the Ethics Committee of Toho University Faculty of Phar-
maceutical Sciences (No.05-20), and performed in accordance with
the Guidelines for the Care and Use of Laboratory Animals of Toho
University.
A total of 4 beagle dogs of either sex weighing about 10 kg were
used. In order to produce proarrhythmia model, the catheter
ablation technique of atrioventricular node was employed (6).
Brieﬂy, the dogs were anesthetized with thiopental sodium (30mg/
kg, i.v.). After proper positioning of the catheter, the radiofrequencynese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Y. Nakamura et al. / Journal of Pharmacological Sciences 131 (2016) 72e75 73energy of 20 W was delivered for 10 s from the tip electrode to an
indifferent patch electrode positioned on the animal's back to
induce complete atrioventricular block.
Experiments were performed 4 weeks after the production of
atrioventricular block (6,7). Two hours after the start of the Holter
ECG recording (QR2100, Fukuda ME Kogyo, Tokyo), oseltamivir in a
dose of 3 mg/kg was intravenously administered over 10 min
without anesthesia (n ¼ 4). Holter ECG was recorded for total of
24 h. Then, 1 week of washout period after the initial experi-
ments, the effects of 10 mg/kg of oseltamivir were assessed in the
same animals (n ¼ 4). Finally, 1 week of washout period after the
second experiments, the effects of 30 mg/kg of oseltamivir were
assessed in the same animals (n ¼ 4). Washout period was deter-
mined by the half-life of oseltamivir that was approximately 12 h
(10).
A Holter analysis system (HS1000, Fukuda ME Kogyo) was used
to examine the electrocardiogram. The QTc was calculated with
Fridericia's formula (11). The QT interval, QTc and idioventricular
automaticity rate were expressed as the mean of 10 consecutive
complexes at pre-drug control (C) and 1, 2, 3, 4, 6, 8, 12 and 21 h
after the drug administration. Torsade de pointes was deﬁned as a
polymorphic ventricular tachycardia, of which QRS complex
twisted around the baseline, lasting 6 consecutive beats (12).
Also, 51 consecutive beats of electrocardiogram under stable idio-
ventricular automaticity were recorded before and 50e60min after
the start of oseltamivir administration. Poincare plots with QTn
versus QTnþ1 were prepared for each of these two analysis time
points, of which short-term variability was calculated by the
following equation: (SjQTnþ1QTnj/[50  √2]) (7,13).
For the action-potential assay, the hearts were isolated from
male Hartley guinea pigs weighing 340e470 g. The right ventric-
ular papillary muscles were quickly dissected and placed in anTime after administration (h)
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Fig. 1. Summary of electrophysiological effects of intravenous oseltamivir. Time courses of t
typical Poincare plots showing the beat to beat variability of QT intervals 20 min before and
neither affected the short-term variability of repolarization (STV) nor induced torsade de p
niﬁcant differences from each pre-drug control value (C) by p < 0.05.organ bath containing KrebseHenseleit solution of the following
composition (in mM): NaCl 118.4, KCl 4.7, CaCl2 2.5, MgSO4 1.2,
KH2PO4 1.2, NaHCO3 24.9, glucose 11.1, gassed with 95% O2/5% CO2
(pH 7.4 at 37 C). Cardiac action potential was recorded as previ-
ously described (9). Brieﬂy, the preparation was driven at a con-
stant frequency of 1 Hz using an electronic stimulator (SEN-2201,
Nihon Kohden, Tokyo) with rectangular current pulses (3-ms
duration, about 1.5 times of threshold) through bipolar platinum
electrodes. They were impaled with glass microelectrodes ﬁlled
with 3 M KCl, and transmembrane potential was recorded with a
microelectrode ampliﬁer (MEZ-8201, Nihon Kohden, Tokyo), and
analyzed using Chart 7 software (AD Instruments, Dunedin, New
Zealand). Action potential parameters measured were resting po-
tential (RP), overshoot (OS), amplitude (AMP), maximum rate of
phase 0 depolarization (Vmax) and action potential duration at 30%
(APD30), 60% (APD60) and 90% (APD90) repolarization levels. Dif-
ference in action-potential duration between 30% and 90% repo-
larization levels (APD30e90) was calculated to estimate the extent of
IKr-inhibitory action (14). All experiments were performed at
36.5 ± 0.5 C.
Oseltamivir was extracted from Tamiﬂu® Capsule (Chugai
Pharmaceutical, Tokyo) with saline in a concentration of 30 mg/mL
and its dose was calculated as its free base. The drug was diluted
with saline in concentrations of 3 and 10 mg/mL for intravenous
use, whereas it was done in distilled water, of which small aliquots
provided desired ﬁnal concentration in the organ bath. The other
drugs usedwere thiopental sodium (Mitsubishi Tanabe Pharma Co.,
Osaka) and heparin calcium (Sawai Pharmaceutical Co. Ltd., Osaka).
The other chemicals were commercial products of the highest
available quality.
Data are presented as the mean ± SEM. The statistical signiﬁ-
cances within a parameter were evaluated by one-way repeated-Time after administration (h)
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Table 1
Effects of oseltamivir on myocardial action potential parameters of the guinea-pig
right ventricular preparation.
Control Oseltamivir
30 mM
Oseltamivir
100 mM
Oseltamivir
300 mM
RP mV 84.3 ± 0.7 83.5 ± 0.5 82.8 ± 0.5 81.7 ± 0.5
OS mV 37.9 ± 1.3 37.4 ± 1.8 35.1 ± 2.0 31.9 ± 2.6*
AMP mV 122.2 ± 1.3 121.0 ± 1.8 117.9 ± 2.4 113.6 ± 3.0*
Vmax V/s 209.9 ± 8.6 209.1 ± 7.0 183.8 ± 4.5* 151.9 ± 6.9***
APD30 ms 152.9 ± 7.4 149.9 ± 8.5 142.1 ± 8.7** 126.2 ± 9.9**
APD60 ms 190.7 ± 5.4 188.9 ± 6.8 184.9 ± 6.7 171.1 ± 7.1**
APD90 ms 205.1 ± 5.9 203.5 ± 6.2 200.7 ± 6.0 188.5 ± 6.4*
APD30e90 ms 52.1 ± 3.5 53.6 ± 3.1 58.6 ± 3.5 62.3 ± 4.2*
Data are expressed as mean ± SEM of 5 experiments. Effects of oseltamivir were
assessed 15 min after the drug application. Action potential duration at 30% (APD30),
60% (APD60) and 90% (APD90) repolarization, resting potential (RP), overshoot (OS),
amplitude (AMP) and maximum rate of phase 0 depolarization (Vmax). The trian-
gulation parameter (APD30e90) was deﬁned as the difference between APD90 and
APD30. *p < 0.05, **p < 0.01, ***p < 0.001 compared with control.
Y. Nakamura et al. / Journal of Pharmacological Sciences 131 (2016) 72e7574measures analysis of variance (ANOVA) followed by Contrasts or
Dunnet's test as post-hoc test formean values comparison, whereas
those of paired datawithin a parameter were evaluated by paired t-
test. A p value < 0.05 was considered to be signiﬁcant.
The time courses of changes in the QT interval, QTc and idio-
ventricular automaticity rate are summarized in Fig. 1A,B and C,
respectively. Oseltamivir in any dose did not induce torsade de
pointes, and all animals survived 21 h after the administration of
each dose. The low dose of 3 mg/kg did not affect the QT interval,
QTc or idioventricular automaticity rate. The middle dose of 10 mg/
kg prolonged the QT interval at 12 h, but it did not affect the QTc or
idioventricular automaticity rate. The high dose of 30 mg/kg pro-
longed the QT interval for 12e21 h, but it decreased the idioven-
tricular rate for 2e21 h, whereas it did not affect the QTc. Typical
Poincare plot of QT intervals for the high dose is depicted in Fig. 1D.
The short-term variability of the QT interval before and after the
drug administrations (n ¼ 4 for each dose) was 3.3 ± 0.6 and
3.4 ± 0.6 ms for the low dose, 3.9 ± 0.6 and 3.6 ± 0.6 ms for the
middle dose, and 3.9 ± 0.6 and 2.9 ± 0.6 ms for the high dose,
respectively. Oseltamivir tended to shorten the short-term vari-
ability in a dose-related manner, although it did not achieve sta-
tistical signiﬁcance.
Typical tracings showing the effects of oseltamivir on the action
potential waveform are depicted in Fig. 2, and the summary of its
effects on the action-potential parameters is shown in Table 1.
Oseltamivir in concentrations of 30e300 mM decreased the OS,
AMP and Vmax, shortened the APD30, APD60 and APD90, but pro-
longed the APD30e90 in a concentration-related manner.
Intravenous oseltamivir did not induce torsade de pointes in the
chronic atrioventricular block dogs, but tended to shorten its short-
term variability, rather reﬂecting modest antiarrhythmic property.
Oseltamivir in intravenous doses of 100, 200 and 400mg over 2 h in
phase I study (2) provided Cmax of 0.263, 0.548 and 1.100 mg/mL,
respectively, and in our previous study using the halothane-
anesthetized dogs, oseltamivir in intravenous doses of 0.3, 3 and
30 mg/kg over 10 min provided peak plasma concentration of 1.2,
10.6 and 117.5 mg/mL, respectively (5), suggesting that plasma
concentration in this study would be about 10e100 times higherFig. 2. Typical tracings showing the effects of oseltamivir on the action-potential
waveform of the right ventricular preparation of guinea pigs. The preparation was
electrically driven at 1 Hz. Black, blue, green and red lines indicate control, 30 mM,
100 mM and 300 mM of oseltamivir, respectively. Black and blue lines run on almost
identical trace, suggesting that oseltamivir of 30 mM did not affect the action potential
waveform. Inserted ﬁgure shows the magniﬁcation of phase 0 depolarization, in which
the horizontal scale is 100 times greater than that of original one, whereas the vertical
scale is common to both ﬁgures.than its therapeutic one. To better clarify its underlying ionic
mechanism, we assessed the effects on the action potential wave-
form. Oseltamivir decreased the Vmax, APD30 and APD60. The former
indicates Naþ channel blocking property, whereas the latters sug-
gest Ca2þ and late Naþ channel inhibition (15). Moreover, the
APD30e90 was prolonged by oseltamivir, suggesting IKr channel
inhibitory action (14). It should be noted that the APD90 was
shortened by oseltamivir, indicating that inhibition of inward cur-
rents may be greater than that of outward ones. These in vitro
observations may partly explain why oseltamivir suppressed the
idioventricular automaticity but did not induce torsade de pointes
in vivo. Oseltamivir carboxylate, a major active metabolite of
oseltamivir did not inhibit IKr channel according to the information
described in the interview form from the manufacturer; however,
further study is needed to conﬁrm the metabolites of oseltamivir in
dogs are identical to those in human. In conclusion, these in vivo
and in vitro observations may suggest that intravenous oseltamivir
by itself has no potential risk to induce torsade de pointes.Conﬂict of interest statement
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